# LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft

Study · id `cardio:ct-nct07773051` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07773051](<https://clinicaltrials.gov/study/NCT07773051>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07773051

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 326 participants.

## Technical summary

Registry record NCT07773051. Randomized; no masking; primary purpose treatment. Start 2025-08-25 (actual); primary completion 2027-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 326 participants (planned count; ClinicalTrials.gov record NCT07773051, source copy `cardio:ctgov-nct07773051-2026-08-19`, retrieved 2026-10-26)
- Started: 2025-08-25 (actual) (ClinicalTrials.gov record NCT07773051, source copy `cardio:ctgov-nct07773051-2026-08-19`, retrieved 2026-10-26)
- Primary completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07773051, source copy `cardio:ctgov-nct07773051-2026-08-19`, retrieved 2026-10-26)
- Completion: 2027-09-30 (anticipated) (ClinicalTrials.gov record NCT07773051, source copy `cardio:ctgov-nct07773051-2026-08-19`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07773051, source copy `cardio:ctgov-nct07773051-2026-08-19`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07773051-2026-08-19`, retrieved 2026-10-26)

## The registry's words

- Brief title: LineMatrix® Biological Vascular Graft for the Creation of Arteriovenous Graft
- Condition: Arteriovenous Graft
- Intervention (Device): LineMatrix® Biological Vascular Graft
- Intervention (Device): GORE-INTERING®
- Lead sponsor: Longhua Hospital
- Lead sponsor class: OTHER
- Collaborator: Humatrix Medical Technology (Suzhou) Co., LTD
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)

## Provenance

Content hash: fb6a0a64aa68a3fb96330be4ce610609231a09ff4d794ba02846af193d257093
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
